- Low BMI is not associated with poorer pain relief from the transdermal fentanyl (TDF) patch for cancer pain, regardless of dose.
Why this matters
- Prior studies of the effectiveness of TDF in patients with low BMI yielded conflicting results.
- This prospective clinical effectiveness study evaluated potential associations among TDF, BMI, and clinical pain outcomes in patients with cancer pain (n=240; median age, 60 years).
- Funding: National Institute on Drug Abuse; others.
- Patients with BMI 2 reported the most pain relief (67%) and lowest least pain (2.7).
- Significant covariate associated with high fentanyl dose and greater least pain was age
- BMI of 2 was significantly associated with greater pain relief irrespective of TDF dose (P=.038).
- The association lost significance after controlling for age, cancer diagnoses, and pain etiology (P=.073).
- Findings may not be generalisable.
Coauthored with Chitra Ravi, MPharm